About us

News

April 2016

AXON Neuroscience becomes a founding member of the Society for CSF Analysis and Clinical Neurochemistry.

March 2016

AXON Neuroscience presented at the 14th Springfield Symposium on Advances in Alzheimer Therapy two topics from its disease modifying AD program . See Press Release for more information.

November 2015

AXON Neuroscience attended the Clinical Trials on Alzheimer´s Disease conference (CTAD) in Barcelona, on November 5-7, 2015. See Press Release for more information.

At a Glance

Axon Neuroscience is a clinical-stage biotech company developing disease-modifying immunotherapeutics for Alzheimer's disease and Frontotemporal lobar degeneration. Ground-breaking discoveries in Alzheimer’s disease research made by AXON Neuroscience enabled the company to create a therapeutic platform of global importance. The target products of strategic importance in this platform are revolutionary therapeutic candidate vaccines for treatment of Alzheimer's disease and Frontotemporal lobar degeneration.

AXON Neuroscience has developed unique animal models that reproduce Alzheimer’s disease and allow for a swift and effective pre-clinical validation of efficacy of new therapeutics and pre-clinical evaluation of diagnostic tools.

Strategically targeted research and development enable AXON Neuroscience to prepare for future production of an extensive assortment of disease modifying pharmaceuticals and diagnostic methods for Alzheimer’s disease.

"It is a great challenge to unravel the molecular basis of the modern plague of mankind - Alzheimer's disease. In order to undertake this challenge, we put together an enthusiastic team of experienced and internationally recognized researchers who can deliver solutions to AD patients."

— Roman Sivak, CEO AXON Neuroscience SE

Mission

Mission - infographic
  • 7 billion worldpopulation
  • 524 million world population over 65
  • 36 million dementia cases
The mission of AXON Neuroscience is to discover and deliver disease modifying immunotherapeutics and enhance the quality of life for patients suffering from Alzheimer's disease and Frontotemporal lobar degeneration.

Management Board

Roman Sivak, Chief Executive Officer

Dipl. Ing. Roman Sivak has graduated with a Master of Economics degree from the University of Economics in Bratislava, Slovak Republic. For most of his professional career he has worked in the financial sector and ran through different managing positions being responsible for several start-up projects and acquisitions. Roman Sivak was also appointed Member of supervisory boards of different companies in industrial and financial sectors.

In January 2011, Roman Sivak was officially appointed by the shareholders of AXON Neuroscience as Chief Executive Officer of AXON Neuroscience.

Norbert Žilka, Chief Science Officer

Norbert Žilka Assoc. Prof, DVM, PhD, has been working for AXON Neuroscience since the foundation of the company in 1999. Norbert Žilka played a key role in AXON Neuroscience's leading discoveries, which he further helped to transform into AXON´s portfolio of products. In 2006 he gained a PhD. in Immunology under the supervision of Prof. Michal Novák. He has devoted 17 years of his life to the research of Alzheimer's disease and is the author of over 50 publications.

Norbert Žilka, was previously responsible for creating novel animal models for human neurodegenerative disorders and preclinical development of AXON’s immunotherapeutics, as Head of preclinical studies. Using animal models, he identified molecular mechanism of interactions between brain immune system and disease modified protein tau. He is considered to be the author of the tau immunological cascade in Alzheimer’s disease. Norbert Žilka was a national coordinator of a project focused on the harmonization of biomarker measurement across Europe, Biomarkers for Alzheimer’s disease and Parkinson’s disease. He is the co-author of the Synaptic Dysfunction in Alzheimer’s Disease, a project funded by Marie Sklodowska-Curie Innovative Training Network and was a national coordinator and chairman of the Neuroscience session at the first Frontiers of Science Meeting organized by the Royal Society and V4 countries in 2010.

Ladislav Satko, Chief Financial Officer

Ladislav Satko has more than a decade of experience in finance and operations. After graduation from Economic university in 2003, he had the opportunity to work in managing a financial position in construction industry in Europe. He followed by being appointed as the Head of Finance of one of the biggest central European publicly traded real estate companies. In November 2011 he was appointed as Chief Financial Officer of AXON Neuroscience, where he is responsible for financial, human resources and IT matters at the company.

Michal Fresser, General Counsel

Michal Fresser finished a Master of Law degree and spent most of his career as responsible person for legal advisory and consulting in one of the largest financial groups in the Central European region.

He experienced the practice on wide portfolio of different industries, with the main focus on mergers and acquisitions, cross-border transactions, corporate and competition law. Michal Fresser has also prior experience in corporate banking sector and arbitration proceeding as Arbitration Associate.

As the General Counsel at AXON Neuroscience, he is responsible and leading all legal, corporate, project and intellectual property matters for the organization.

Michal Novak, Co-founder of AXON Neuroscience and Chairman of the Scientific Advisory Board

See Scientific Advisory Board for more information.

Scientific Advisory Board

  • Michal Novak, Chairman


    Michal Novák DVM, PhD is a neuroscientist, immunologist, and educator. In 1999, together with Martin Cabadaj, they founded a biotech company AXON Neuroscience with the mission to discover and deliver disease modifying immunotherapeutics for patients suffering from Alzheimer´s disease. He is currently a professor and founding director of the Institute of Neuroimmunology at the Slovak Academy of Sciences. He has devoted twenty-six years of his career to the research of Alzheimer's disease. He published more than 135 research papers which have been cited more than 3,500 times.

    A major part of his work has been performed at the MRC Laboratory of Molecular Biology in Cambridge, UK and at ISAS Trieste, Italy. He was a member of international research teams led by Nobel Prize laureates Sir Aaron Klug, Cesar Milstein, and John Walker. The group discovered that pathologically modified brain protein tau constitutes one of the major hallmarks of Alzheimer's disease – neurofibrillary tangles.

    Prof. Novák was International Scholar of the Howard Hughes Medical Institute, Maryland, USA (1995 – 2000) and received grant awards from Human Frontiers Science Organization, Strasbourg, France, and from Howard Hughes Medical Institute. He is also a Founding President of the Slovak Alzheimer’s Society and a co-founder and President of the Slovak Society for Neuroscience. From 2008 to 2012, he was a member of the Executive Committee of the Federation of European Neuroscience Societies (FENS). He is also a co-founder and a board member of the largest global research initiative aimed at tackling the challenges of neurodegenerative diseases, EU Joint Programme - Neurodegenerative Disease Research (JPND).

  • Khalid Iqbal, Co-Chairman


    Khalid Iqbal, Ph.D., is Professor and Chairman of Neurochemistry at the New York State Institute for Basic Research in Developmental Disabilities, Staten Island, New York. He received his Ph.D. in Biochemistry in 1969 from the University of Edinburgh, Edinburgh, U.K.

    In 1986 he, along with Dr. Inge Grundke-Iqbal, discovered the presence of all six molecular isoforms of tau protein in PHF and showed that tau in PHF is abnormally hyperphosphorylated. The same year, Dr. Iqbal was the first to show that the abnormally hyperphosphorylated tau in the AD brain cytosol inhibited the in vitro microtubule assembly. In 1993, his laboratory discovered a specific decrease in the activities of protein phosphatases (PP) -2 and PP-1 in AD brain. Dr. Iqbal has authored over 200 scientific papers in prestigious American and international scientific journals.

    His pioneering studies on neuronal protein pathology and discoveries of tau protein and its abnormal hyperphosphorylation in Alzheimer disease has won him many prestigious honors and awards, including the Potamkin Prize for Alzheimer Disease research from the American Academy of Neurology, and the Zenith Award from the Alzheimer’s Association, USA.

    He is a Founder and Chairman of the International Conference on Alzheimer Disease and Related Disorders (ICAD). In 2007, Alzheimer’s Association, USA, established a Khalid Iqbal Life Time Achievement Award for Alzheimer’s disease Research, which is given out annually at the Alzheimer’s Association International Conference (AAIC).

  • Ezio Giacobini


    Professor (University Hospitals Geneva, Switzerland)

  • Irina Alafuzoff


    Professor of General Pathology and Neuropathology (Uppsala University, Sweden)

  • Constantin Bouras


    Professor (University Hospitals Geneva, Switzerland)

  • Bengt Winblad


    Professor of Geriatric medicine (Karolinska Institutet, Sweden)

Clinical Advisory Board

AXON Neuroscience has assembled an international team of leading experts in the field of Alzheimer’s disease and clinical drug development to support the designs, conducts, and analyses of AXON Neuroscience clinical trials for new treatments of Alzheimer’s disease and other related neurodegenerative disorders.

  • Bengt Winblad, Chairman


    Professor of geriatric medicine in Sweden. His research interests include epidemiology of dementias, clinical evaluation and treatment of dementia conditions, especially Alzheimer’s disease, and the molecular genetics, pathology, and biochemistry of dementias. Bengt Winblad has published more than 700 original publications in gerontology, geriatrics, and dementia research.

  • Reinhold Schmidt


    Professor of Neurology (Austria), Leading expert in MRI analysis and evaluation

  • Khalid Iqbal


    Professor of Neurochemistry (Staten Island, New York, U.S.A.)

  • Lutz Frölich


    Professor of Psychiatry (Germany)

  • Jakub Hort


    Professor of Neurology (Czech Republic)

  • Dietmar Fuchs


    Professor of Immunology (Austria)

  • John Harrison


    Leading expert in Psychology and cognitive testing

  • David Fleet


    Leading expert in Biostatistics of neurodegenerative disorders

  • Niels Andreasen


    Leading expert in Neuro-Geriatrics (Sweden)

History

AXON Neuroscience as a gold level sponsor has organized a Symposium at the Alzheimer´s Association International Conference (AAIC), the largest Alzheimer´s and dementia conference in the world, in Washington, D.C.

March 2015

Recruitment of patients for AADvac1 phase I study has been completed

August 2014

Prof. Michal Novak presented new clinical data from the ongoing AADvac1 phase I study at the Alzheimer Association International Conference in Copenhagen (July 12-17, 2014)

December 2013

The first patient was vaccinated with AADvac1

May 2013

AXON Neuroscience presented its therapeutic strategies at the AD/PD 2013 international conference in Florence

2012

AXON Neuroscience confirmed the in vivo efficacy of its vaccines in preclinical studies using AD transgenic rat models

2009

AXON Neuroscience initiated a revolutionary immunotherapy program

2006

AXON Neuroscience developed the first AD transgenic rat model and validated Alzheimer tau as a major cause of AD neurodegeneration. The model was presented in the "Hot Topics Session" at the 9th International Conference on AD (ICAD), Philadelphia in July 2004

2002

AXON Neuroscience discovered and characterized a particular form of the truncated tau protein with a causal role in AD - Alzheimer tau

1999

Michal Novak proposed that truncated tau species display features similar to prions and therefore he designated them as tauons

1991

While working with three Nobel Laureates - Cesar Milstein, Aaron Klug and John Walker - at MRC LMB Cambridge, UK, Michal Novak created a monoclonal antibody (MN423) that was instrumental in the discovery of tau protein as an integral constituent of neurofibrillary tangles – a major hallmark of Alzheimer's disease

July 2015

AXON Neuroscience successfully finished phase 1 Study with AADvac1

December 2014

AXON Neuroscience and MRC Technology announced successful humanization of Anti-Tau Monoclonal Antibody for Alzheimer’s disease therapy. See Press Release for more information

July 2014

Axon Neuroscience has received final approval from the Regulatory Authority and Central Ethics Committee in Graz to start a AADvac1 phase I follow-up study

July 2013

First-in-man clinical trial with the first active immunotherapy directed against neurofibrillary tau pathology in Alzheimer’s disease was approved by the Regulatory Authority and Central Ethics Committee in Graz

March 2013

AXON Neuroscience started GMP (good manufacturing practice) vaccine production and finished its GLP (good laboratory practice) toxicology and safety pharmacology studies

2009-2011

AXON Neuroscience uncovered the mechanism of how Alzheimer tau induces neuroinflammation

AXON Neuroscience discovered the most vulnerable area of Alzheimer tau - the Achilles heel of Alzheimer tau

Using knowledge of the 3D structure of the tau Achilles heel, AXON Neuroscience produced tau peptide vaccines

2007

AXON Neuroscience showed that Alzheimer tau is an inducer of oxidative stress

2003

AXON Neuroscience has developed an integrated set of new immunological, biochemical, and cell assays devoted to drug screening and validation

2001

AXON Neuroscience was founded as a biotech company focusing on Alzheimer's disease therapy (Michal Novak was a co-founder of the company)

1994

Michal Novak discovered tau truncation as the most productive post-translational modification in Alzheimer's disease and simultaneously designated truncated tau as a driving force of the neurofibrillary degeneration in Alzheimer's disease

1988

Research & Development

Discovery Programs

Alzheimer Tau

Alzheimer Tau

AXON Neuroscience has more than 500 cumulative years of experience in neuroimmunology research. AXON Neuroscience has developed a novel approach using monoclonal antibodies as structural imprints of diseased forms of tau proteins isolated from Alzheimer's disease brains. These imprints have been used to identify a novel target for AD therapy – Alzheimer tau.

AXON Immunotherapy program

AXON Alzheimer‘s disease immunotherapy program (ADIP)

AXON Neuroscience is developing new immunotherapeutics targeting Alzheimer tau that can prevent the formation of tau oligomers and neurofibrillary tangles and thus protect the brain from neurodegeneration. These therapeutic approaches have been tested in preclinical studies in AXON animal models. AXON Neuroscience developed active and passive vaccines that eliminate Alzheimer tau by targeting its most vulnerable part.

AXON Alzheimer's disease diagnostic program

AXON Alzheimer's disease diagnostic program (ADDP)

AXON Neuroscience discovered a novel pathological form of tau protein critical for development of AD and present only in AD patients. Based on this knowledge, AXON Neuroscience is developing new diagnostic tools for early and late stages of AD.

AXON Alzheimer's disease preclinical platforms

AXON Alzheimer's disease preclinical platforms (ADPP)

AXON Neuroscience has generated transgenic rat and mouse models recapitulating the main pathological features of Alzheimer's disease such as neurofibrillary degeneration, neuroinflammation, synaptic failure, oxidative stress, and neurobehavioural changes. The models are used for preclinical efficacy studies with AXON active and passive vaccines, identification of novel diagnostic biomarkers in the cerebrospinal fluid and blood, and for development of anti-inflammatory AD therapy.

  • AXON bio-fluid diagnostic platform

    AXON animal models are critical for identification of potential diagnostic proteome and peptidome-based disease-specific biomarkers in cerebrospinal fluid.

  • AXON in-flame platform

    AXON animal models are ideally suited for validation of new drugs targeting specific inflammatory pathways involved in Alzheimer's disease.

AXON Frontotemporal lobar degeneration immunotherapy program (AFTIP)

AXON Frontotemporal lobar degeneration immunotherapy program (AFTIP)

An estimated 20% of patients affected by dementia suffer from Frontotemporal lobar degeneration (FTLD). Our preclinical studies showed that tau Achilles heel is involved in the pathogenesis of FTLD and thus represents a specific target for immunotherapy. AXON Neuroscience is about to launch a clinical trial on AADvac1 vaccine in patients suffering from FTLD.

Intellectual Property

AXON Neuroscience holds intellectual property rights:

  • to pathologically modified tau species derived from Alzheimer's disease brain tissues – the Alzheimer tau family – that directly correlate with the cognitive decline of AD patients
  • to the use of Alzheimer tau as a therapeutic drug target
  • to unique therapeutic and diagnostic antibodies, as well as their fragments, portions, and derivatives that bind specific regions of the Alzheimer tau protein responsible for the initiation and propagation of pathological tau-tau interactions
  • to methods of using these antibodies for diagnostics, prevention, and treatment of Alzheimer's disease and related human tauopathies
  • to antibodies and/or peptide vaccines that elicit an immune response directed to pathological tau proteins and tau deposits in patient brains
  • to transgenic non-human animal models expressing the Alzheimer tau protein

Publications

AXON Neuroscience has published a number of valuable original research papers in several prestigious scientific journals. The papers focus on structural neuroscience, neuroimmunology and neuroproteomics of Alzheimer's disease.

  • Therapeutic Visions
  • Animal Models
  • Neuroprotemonics
  • TitleIdentification of structural determinants on tau protein essential for its pathological function: novel therapeutic target  for tau immunotherapy in Alzheimer's disease
  • AuthorsKontsekova E, Zilka N, Kovacech B, Skrabana R, Novak M.
  • JournalAlzheimers Res Ther. 2014 Aug 1;6(4):45.
  • TitleFirst-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau  oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model
  • AuthorsKontsekova E, Zilka N, Kovacech B, Novak P, Novak M.
  • JournalAlzheimers Res Ther. 2014 Aug 1;6(4):44.
  • TitleCan we teach old dogs new tricks? Neuroprotective cell therapy in Alzheimer's and Parkinson's disease.
  • AuthorsKazmerova Z, Zilka N, Cente M, Neradil P, Zilkova M, Novak M.
  • JournalJ Alzheimers Dis. 2013; 37(2):251-72
  • TitleWho fans the flames of Alzheimer's disease brains? Misfolded tau on the crossroad of neurodegenerative and inflammatory  pathways
  • AuthorsZilka N, Kazmerova Z, Jadhav S, Neradil P, Madari A, Obetkova D, Bugos O, Novak M.
  • JournalJ Neuroinflamm. 2012; 9:47
  • TitleChaperone-Like Antibodies in Neurodegenerative Tauopathies: Implication for Immunotherapy
  • AuthorsKontsekova E, Ivanovova N, Handzusova M, Novak M.
  • JournalCell Mol Neurobiol. 2009; 29:793-798
  • TitleChaperone-like antibodies targeting misfolded tau protein: new vistas in the immunotherapy of neurodegenerative  foldopathies
  • AuthorsZilka N, Kontsekova E, Novak M.
  • JournalJ Alzheimers Dis. 2008; 15(2):169-79.
  • TitleOf rodents and men: the mysterious interneuronal pilgrimage of misfolded protein tau in Alzheimer’s disease.
  • AuthorsLevarska L, Zilka N, Jadhav S, Neradil P, Novak M.
  • JournalJ Alzheimers Dis. 2013; 37(3):569-77
  • TitleImmunomodulation of Memory-Impairing Protein Tau in Alzheimer's Disease
  • AuthorsZilka N, Stozicka Z, Kazmerova Z, Cente M, Kovacech B, Novak M.
  • JournalNeurodegenerative Dis. 2012; 10:242-245
  • TitleFirst transgenic rat model developing progressive cortical neurofibrillary tangles
  • AuthorsFilipcik P, Zilka N, Bugos O, Kucerak J, Koson P, Novak P, Novak M.
  • JournalNeurobiol Aging 2012; 33:1448-1456
  • TitleHyperphosphorylated truncated protein tau induces caspase 3 independent apoptotic-like pathway in the AD cellular  model
  • AuthorsZilkova M, Zilka N, Kovac A, Kovacech B, Skrabana R, Skrabanova M, Novak M.
  • JournalJ Alzheimers Dis. 2011; 23:161-173
  • TitleGenetic background modifies neurodegeneration and neuroinflammation driven by misfolded human tau protein in rat  model of tauopathy: implication for immunomodulatory approach to Alzheimer's disease
  • AuthorsStozicka Z, Zilka N, Novak P, Kovacech B, Bugos O, Novak M.
  • JournalJ Neuroinflamm. 2010; 7:64
  • TitleCSF phospho-tau correlates with behavioural decline and brain insoluble phospho-tau levels in a rat model of tauopathy
  • AuthorsZilka N, Korenova M, Kovacech B, Iqbal K, Novak M.
  • JournalActa Neuropath. 2010; 119:679-387
  • TitleMisfolded tau protein and disease modifying pathways in transgenic rodent models of human tauopathies
  • AuthorsZilka N, Korenova M, Novak M.
  • JournalActa Neuropath. 2009; 118:71-86
  • TitleExpression of a truncated human tau protein induces aqueous-phase free radicals in a rat model of tauopathy –  implications for targeted antioxidative therapy
  • AuthorsCente M, Filipcik P, Mandakova S, Zilka N, Krajciova G, Novak M.
  • JournalJ Alzheimers Dis. 2009; 17:913-920
  • TitleBeyond the rat models of human neurodegenerative disorders
  • AuthorsBugos O, Bhide M, Zilka N.
  • JournalCell Mol Neurobiol. 2009; 29:859-869
  • TitleMemantine Prevents Sensitivity to Excitotoxic Cell Death of Rat Cortical Neurons Expressing Human Truncated
     Tau Protein
  • AuthorsCente M, Mandakova S, Filipcik P.
  • JournalCell Mol Neurobiol. 2009; 29:945-949
  • TitleCortical and Hippocampal Neurons from Truncated Tau Transgenic Rat Express Multiple Markers of Neurodegeneration
  • AuthorsFilipcik P, Cente M, Krajciova G, Vanicky I, Novak M.
  • JournalCell Mol Neurobiol. 2009; 29:895-900
  • TitleHuman misfolded truncated tau protein promotes activation of microglia and leukocyte infiltration in the transgenic
     rat model of tauopathy
  • AuthorsZilka N, Stozicka Z, Kovac A, Pilipcinec E, Bugos O, Novak M.
  • JournalJ Neuroimmunol. 2009; 209 (1-2):16-25.
  • TitleNeuroScale, the battery of behavioral tests with novel scoring system for phenotyping of transgenic rat model
     of tauopathy
  • AuthorsKorenova M, Zilka N, Stozicka Z, Bugos O, Vanicky I, Novak M.
  • JournalJ Neurosci Methods. 2009; 177(1):108-14.
  • TitleTruncated tau expression levels determine life span of a rat model of tauopathy without causing neuronal loss
     or correlating with terminal neurofibrillary tangle load
  • AuthorsKoson P, Zilka N, Kovac A, Kovacech B, Korenova M, Filipcik P, Novak M.
  • JournalEur J Neurosci. 2008; 28(2):239-46.
  • TitleNeurodegeneration caused by expression of human truncated tau leads to progressive neurobehavioural impairment
     in transgenic rats
  • AuthorsHrnkova M, Zilka N, Minichova Z, Koson P, Novak M.
  • JournalBrain Res. 2007; 1130(1):206-13.
  • TitleExpression of a truncated tau protein induces oxidative stress in a rodent model of tauopathy
  • AuthorsCente M, Filipcik P, Pevalova M, Novak M.
  • JournalEur J Neurosci. 2006; 24(4):1085-90.
  • TitleN-terminal truncation of microtubule associated protein tau dysregulates its cellular localization
  • AuthorsPaholikova K, Salingova B, Opattova A, Skrabana R, Majerova P, Zilka N, Kovacech B, Zilkova M, Barath P, Novak M.
  • JournalJ Alzheimers Dis. 2015;43(3):915-26.
  • TitleMicroglia display modest phagocytic capacity for extracellular tau oligomers.
  • AuthorsMajerova P, Zilkova M, Kazmerova Z, Kovac A, Paholikova K, Kovacech B, Zilka N, Novak M.
  • JournalJ Neuroinflammation. 2014 Sep 13;11(1):161.
  • TitleLiquid chromatography-tandem mass spectrometry method for determination of panel of neurotransmitters in  cerebrospinal fluid from the rat model for tauopathy
  • AuthorsKovac A, Somikova Z, Zilka N, Novak M.
  • JournalTalanta. 2014 Feb;119:284-90.
  • TitleLiquid Chromatography-Tandem Mass Spectrometry Method for Determination of Homocysteine in Rat Plasma:  Application to the Study of a Rat Model for Tauopathies
  • AuthorsKovac A, Svihlova K, Michalicova A, Novak M.
  • JournalJ Chromatogr Sci. 2014 Dec 2.
  • TitleLiquid chromatography-tandem mass spectrometry method for determination of panel of neurotransmitters in  cerebrospinal fluid from the rat model for tauopathy
  • AuthorsKovac A, Somikova Z, Zilka N, Novak M.
  • JournalTalanta. 2014; 119:284-90
  • TitleProtein truncation as a common denominator of human neurodegenerative foldopathies.
  • AuthorsJadhav S, Zilka N, Novak M.
  • JournalMol Neurobiol. 2013; 48(3):516-32
  • TitleIntracellular degradation of misfolded tau protein induced by geldanamycin is associated with activation of proteasome
  • AuthorsOpattova A, Filipcik P, Cente M, Novak M.
  • JournalJ Alzheimers Dis. 2013; 33(2):339-48.
  • TitleCrystallization and preliminary X-ray diffraction analysis of two peptides from Alzheimer PHF in complex with the MN423  antibody Fab fragment
  • AuthorsSkrabana R, Cehlar O, Flachbartova Z, Kovac A, Sevcik J, Novak M.
  • JournalActa Crystallogr Sect F Struct Biol Cryst Commun. 2012; 68(Pt 10):1186-90.
  • TitleCrystallization and preliminary X-ray diffraction analysis of tau protein microtubule-binding motifs in complex with Tau5  and DC25 antibody Fab fragments
  • AuthorsCehlar O, Skrabana R, Kovac A, Kovacech B, Novak M.
  • JournalActa Crystallogr Sect F Struct Biol Cryst Commun. 2012; 68(Pt 10):1181-5.
  • TitleThe self-perpetuating tau truncation circle
  • AuthorsZilka N, Kovacech B, Barath P, Kontsekova E, Novak M.
  • JournalBiochem Soc Trans. 2012; 40:681-686
  • TitleMisfolded Truncated Protein tau Induces Innate Immune Response via MAPK Pathway
  • AuthorsKovac A, Zilka N, Kazmerova Z, Cente M, Zilkova M, Novak M.
  • JournalJ Immunol. 2011; 187:2732-2739
  • TitleTau Truncation is a Productive Posttranslational Modification of Neurofibrillary Degeneration in Alzheimer's Disease
  • AuthorsKovacech B, Novak M.
  • JournalCurr Alz Res. 2010; 7: 708-716
  • TitleMonoclonal antibody MN423 as a stable mold facilitates structure determination of disordered tau protein
  • AuthorsSkrabana R, Dvorsky R, Sevcik J, Novak M.
  • JournalJ Struct Biol. 2010; 171: 74-81
  • TitleTransition of Tau Protein from Disordered to Misordered in Alzheimer's Disease
  • AuthorsKovacech B, Skrabana R, Novak M.
  • JournalNeurodegenerative Dis. 2010; 7:24-27
  • TitleNew age of neuroproteomics in Alzheimer's disease research
  • AuthorsKovacech B, Zilka N, Novak M.
  • JournalCell Mol Neurobiol. 2009; 29:799-805
  • TitleStructure solution of misfolded conformations adopted by intrinsically disordered Alzheimer's tau protein
  • AuthorsSevcik J, Skrabana R, Kontsekova E, Novak M.
  • JournalProtein Pept Lett. 2009; 16(1):61-4.
  • TitleRat tau proteome consists of six tau isoforms: Implication for animal models of human tauopathies
  • AuthorsHanes J, Zilka N, Bartkova M, Caletkova M, Dobrota D, Novak M.
  • JournalJ Neurochem. 2009; 108, 1167–1176.
  • TitlePreserving free thiols of intrinsically disordered tau protein without the use of a reducing agent
  • AuthorsKrajciova G, Skrabana R, Filipcik P, Novak M.
  • JournalANALYTICAL BIOCHEMISTRY. 2008; 383(2):343-345.
  • TitleHigh-yield purification of fetal tau preserving its structure and phosphorylation pattern
  • AuthorsIvanovova N, Handzusova M, Hanes J, Kontsekova E, Novak M.
  • JournalJ Immunol Methods. 2008; 339(1):17-22.
  • TitleX-ray structure of the PHF core C-terminus: insight into the folding of the intrinsically disordered protein tau in  Alzheimer's disease
  • AuthorsSevcik J, Skrabana R, Dvorsky R, Csokova N, Iqbal K, Novak M.
  • JournalFEBS Lett. 2007; 581(30):5872-8.
  • TitleA novel monoclonal antibody DC63 reveals that inhibitor 1 of protein phosphatase 2A is preferentially nuclearly localised  in human brain
  • AuthorsKovacech B, Kontsekova E, Zilka N, Novak P, Skrabana R, Filipcik P, Iqbal K, Novak M.
  • JournalFEBS Lett. 2007; 581(4):617-22.
  • TitlePreparation, crystallization and preliminary X-ray analysis of the Fab fragment of monoclonal antibody MN423, revealing  the structural aspects of Alzheimer's paired helical filaments
  • AuthorsCsokova N, Skrabana R, Urbanikova L, Kovacech B, Sevcik J, Novak M.
  • JournalProtein Pept Lett. 2006; 13(9):941-4.
  • TitleAlzheimer's-disease-associated conformation of intrinsically disordered tau protein studied by intrinsically disordered  protein liquid-phase competitive enzyme-linked immunosorbent assay
  • AuthorsSkrabana R, Skrabanova-Khuebachova M, Kontsek P, Novak M.
  • JournalAnal Biochem. 2006; 359(2):230-7.
  • TitleIntrinsically disordered proteins in the neurodegenerative processes: formation of tau protein paired helical filaments  and their analysis
  • AuthorsSkrabana R, Sevcik J, Novak M.
  • JournalCell Mol Neurobiol. 2006; 26(7-8):1085-97.
  • TitleFirst insert of tau protein is present in all stages of tau pathology in Alzheimer's disease
  • AuthorsSoltys K, Rolkova G, Vechterova L, Filipcik P, Zilka N, Kontsekova E, Novak M.
  • JournalNeuroreport. 2005; 16(15):1677-81.
  • TitleAlzheimer paired helical filaments (PHFs) studied by high-resolution TEM: what can vertical Pt-C replication tell us about  the organization of the pronase-digested PHF core?
  • AuthorsRuben GC, Novak M, Edwards PC, Iqbal K.
  • JournalMicrosc Res Tech. 2005; 67(3-4):196-209.
  • TitleFolding of Alzheimer's core PHF subunit revealed by monoclonal antibody 423
  • AuthorsSkrabana R, Kontsek P, Mederlyova A, Iqbal K, Novak M.
  • JournalFEBS Lett. 2004; 568(1-3):178-82.
  • TitleRapid purification of truncated tau proteins: model approach to purification of functionally active fragments of  disordered proteins, implication for neurodegenerative diseases
  • AuthorsCsokova N, Skrabana R, Liebig HD, Mederlyova A, Kontsek P, Novak M.
  • JournalProtein Expr Purif. 2004; 35(2):366-72.
  • TitleDC11: a novel monoclonal antibody revealing Alzheimer's disease-specific tau epitope
  • AuthorsVechterova L, Kontsekova E, Zilka N, Ferencik M, Ravid R, Novak M.
  • JournalNeuroreport. 2003 Jan 20;14(1):87-91.
  • TitleMapping the C terminal epitope of the Alzheimer's disease specific antibody MN423
  • AuthorsKhuebachova M, Verzillo V, Skrabana R, Ovecka M, Vaccaro P, Panni S, Bradbury A, Novak M.
  • JournalJ Immunol Methods. 2002 Apr 1;262(1-2):205-15.

Clinical trials

Klinische Prüfungen

Klinické skúšania

Klinické testování

AADvac1 AD Phase I Study

This first- in-man phase I study is designed to assess the safety and tolerability of AADvac1 for the treatment of Alzheimer's disease. Efficacy will be assessed in an exploratory manner.

AADvac1 is an active immunotherapy directed against pathologically modified Alzheimer tau protein that is the main constituent of neurofibrillary tangles (NFTs). It is intended to be a disease-modifying treatment for Alzheimer's disease, aiming to halt its progress.

AADvac1 phase 1 clinical trial has now been completed.

Approvals:

The study is carried out in accordance with the ethical and scientific principles of Declaration of Helsinki, the ICH Guideline on Good Clinical Practice, the EU Clinical Trials Directive, as well as local regulations.

Data Safety Monitoring Board consisting of internationally recognized medical and scientific experts, Prof. Bengt Winblad, Prof. Lutz Frölich, and Prof. Dietmar Fuchs has been established to assess the safety and tolerability profile of AADvac1.

Additional information can be found on: http://www.clinicaltrials.gov/ct2/show/NCT01850238

Study Sites in Austria:

Wien

Salzburg

Graz

Universitätsklinik für Neurologie, PMU, Christian-Doppler Klinik
  • Salzburg, Austria, 5020
  • www.salk.at
  • Wolfgang Staffen, Professor
Recruiting finished
Medizinische Universität Wien
Sozialmedizinisches Zentrum Ost Donauspital
Recruiting finished
Medizinische Universität Graz
Recruiting finished

AADvac1 AD Follow up Study

The 18-month follow-up study is designed to assess the long term safety and tolerability of AADvac1 in the treatment of Alzheimer's disease as well as persistence of the immune response to AADvac1 in patients who have completed the AADvac1 phase I study.

AADvac1 is an active immunotherapy directed against pathologically modified Alzheimer tau protein that is the main constituent of neurofibrillary tangles (NFTs). It is intended to be a disease-modifying treatment for Alzheimer's disease, aiming to halt its progress.

Approvals:

The study is carried out in accordance with the ethical and scientific principles of Declaration of Helsinki, the ICH Guideline on Good Clinical Practice, the EU Clinical Trials Directive, as well as local regulations.

Data Safety Monitoring Board consisting of internationally recognized medical and scientific experts, Prof. Bengt Winblad, Prof. Lutz Frölich, and Prof. Dietmar Fuchs has been established to assess the safety and tolerability profile of AADvac1.

Additional information can be found on: http://www.clinicaltrials.gov/ct2/show/NCT02031198

Study Sites in Austria:

Wien

Salzburg

Graz

Universitätsklinik für Neurologie, PMU, Christian-Doppler Klinik
  • Salzburg, Austria, 5020
  • www.salk.at
  • Wolfgang Staffen, Professor
Recruiting
Medizinische Universität Wien
Sozialmedizinisches Zentrum Ost Donauspital
Recruiting
Medizinische Universität Graz
Recruiting

AADvac1 AD Phase II Study

AADvac1 AD Phase II Studie

Skúšanie AADvac1 AD Fáza II

Testování AADvac1 AD Fáze II

Language:Sprache:Jazyk:Jazyk:

ADAMANT AADvac1 phase II study is a 24-months randomized, placebo-controlled, parallel group, double-blinded, multicentre study to assess safety and efficacy of the first tau active vaccine AADvac1 in patients with mild Alzheimer´s disease.

AADvac1 is an active immunotherapy directed against pathologically modified Alzheimer tau protein that is the main constituent of neurofibrillary tangles (NFTs). It is intended to be a disease-modifying treatment for Alzheimer´s disease.

Phase II study is designed to explore two main objectives to gain more data. The primary objective is to assess the safety and tolerability, and the second objective is to assess the efficacy of AADvac1 and potential biomarkers.

AADvac1 phase II clinical study will be conducted in 8 countries of Europe and 185 patients will be enrolled in the study.

Approvals:

The study is carried out in accordance with the ethical and scientific principles of Declaration of Helsinki, the ICH Guidelines, Good Clinical Practise, the EU Clinical Trials Directives, as well as local regulations.

Data Safety Monitoring Board consisting of internationally recognized medical and scientific experts has been established to assess the safety and tolerability profile of AADvac1.

Additional information can be found on: https://clinicaltrials.gov/ct2/show/study/NCT02579252

To learn more please contact us at adamant@axon-neuroscience.eu

Study Sites in Europe:

Die ADAMANT AADvac1 Phase II Studie ist eine randomisierte, Placebo kontrollierte, multizentrische, doppelblinde Parallelgruppen Studie über 24 Monate zur Beurteilung der Sicherheit und Wirksamkeit des ersten aktiven Impfstoffs gegen Tau-Protein bei Patienten mit der leichten Form der Alzheimer-Krankheit.

Der Impfstoff AADvac1 stellt eine aktive Immuntherapie dar, die gegen pathologisch modifiziertes Tau-Protein der Alzheimer-Krankheit wirkt, welches Hauptbestandteil der Neurofibrillenbündel ist. Die Behandlung ist darauf ausgelegt, das Fortschreiten der Alzheimer-Krankheit zu beeinflussen.

Die Phase II Studie is darauf ausgerichtetet, Daten im Hinblick auf zwei Hauptziele zu gewinnen. Das erste Ziel ist die Bewertung der Sicherheit und Toleranz für die Patienten und das zweite Ziel ist die Beurteilung der Wirksamkeit des Impfstoffs AADvac1 und potenzieller Biomarker.

Die Phase II Studie mit AADvac1 wird in 8 europäischen Ländern mit insgesamt 185 teilnehmenden Patienten durchgeführt.

Genehmigungen:

Diese klinische Prüfung wird im Einklang mit ethischen Prinzipien und wissenschaftlichen Grundsätzen der Deklaration von Helsinki, der Richtlinie der Internationalen Konferenz zur Harmonisierung zur Guten Klinischen Praxis, den EU Richtlinien zu klinischen Prüfungen sowie gemäß länderspezifischer Vorschriften realisiert.

Zum Zweck der Überwachung der Datensicherheit wurde ein Gremium aus international anerkannten Experten aus dem Bereich der Medizin und Wissenschaft gebildet, deren Aufgabe ist, das Sicherheits- und Toleranzprofil des Impfstoffs AADvac1 zu beurteilen.

Weitere Informationen finden Sie hier: https://clinicaltrials.gov/ct2/show/study/NCT02579252

Wenn Sie ausführliche Informationen möchten, kontaktieren Sie uns unter adamant@axon-neuroscience.eu

Studienzentren in Europa:

Klinické skúšanie ADAMANT AADvac1 Fáza II je 24-mesačné randomizované, placebom kontrolované, dvojito zaslepené, multicentrické klinické skúšanie s paralelnými skupinami, hodnotiace bezpečnosť a účinnosť AADvac1, prvej vakcíny pôsobiacej na proteín tau, ktorá sa podáva pacientom s miernou Alzheimerovou chorobou.

Vakcína AADvac1 predstavuje aktívnu imunoterapiu pôsobiacu proti patologicky modifikovanému proteínu tau, ktorý je hlavnou zložkou neurofibriálnych klbiek v Alzheimerovej chorobe. Ide o liečbu, ktorá by mala mať vplyv na postup Alzheimerovej choroby.

Účelom klinického skúšania fázy II je preskúmať dva hlavné ciele. Prvým cieľom je získať viac údajov o bezpečnosti a tolerovateľnosti u pacientov a druhým cieľom je posúdiť účinnosti vakcíny AADvac1 a vplyv na potenciálne biomarkery.

AADvac1 klinické skúšanie fázy II bude vykonané v 8 krajinách Európy a bude doň zaradených 185 pacientov.

Schválenia:

Toto klinické skúšanie sa vykonáva v súlade s etickými a vedeckými zásadami Helsinskej deklarácie, Smerníc Medzinárodnej konferencie pre harmonizáciu o správnej klinickej praxi, Smerníc EÚ o klinickom skúšaní, a s miestnou legislatívou.

Bola ustanovená rada pre monitorovanie bezpečnosti dát zložená z medzinárodne uznávaných expertov v oblasti zdravotníctva a vedy, ktorej úlohou je posudzovať bezpečnosť a tolerovateľnosť vakcíny AADvac1.

Ďalšie informácie sú k dispozícii na: https://clinicaltrials.gov/ct2/show/study/NCT02579252

Ak máte záujem o podrobnejšie informácie, kontaktujte nás na adamant@axon-neuroscience.eu

Pracoviská skúšania v Európe:

Klinické testování ADAMANT AADvac1 Fáze II je 24měsíční randomizované, placebem kontrolované, dvojitě zaslepené, multicentrické klinické testování s paralelními skupinami, hodnotící bezpečnost a účinnost AADvac1, první vakcíny působící na protein tau, která se podává pacientům s mírnou formou Alzheimerovy nemoci.

Vakcína AADvac1 představuje aktivní imunoterapii, která působí proti patologicky modifikovanému proteinu tau Alzheimerovy nemoci, který je hlavní složkou neurofibrilárních klubek. Jde o léčbu, která by měla mít vliv na postup Alzheimerovy nemoci.

Účelem fáze II tohoto klinického testování je prozkoumat dva hlavní cíle, abychom získali více údajů. Prvním cílem je posoudit bezpečnost a snášenlivost pro pacienty, a druhým cílem je posoudit účinnosti vakcíny AADvac1 a potenciálních biomarkerů.

Klinické testování AADvac1 fáze II bude provedeno v 8 evropských zemích a bude do něj zapojeno 185 pacientů.

Schválení:

Toto klinické testování se provádí v souladu s etickými a vědeckými zásadami Helsinské deklarace, směrnic Mezinárodní konference pro harmonizaci o správné klinické praxi, směrnic EU o klinickém testování, a s místními předpisy.

Byla ustanovena rada pro monitorování bezpečnostních dat, složená z mezinárodně uznávaných odborníků v oblasti zdravotnictví a vědy, jejíž úlohou je posuzovat bezpečnost a snášenlivost vakcíny AADvac1

Další informace jsou k dispozici na: https://clinicaltrials.gov/ct2/show/study/NCT02579252

Pokud máte zájem o podrobnější informace, kontaktujte nás na adamant@axon-neuroscience.eu

Testovací pracoviště v Evropě:

Back to map
Univerzitná nemocnica L. Pasteura Košice
  • Psychiatrická klinika
  • Rastislavova 43, 041 90 Košice
  • www.unlp.sk
  • Slávka Dubinská, MD
MUDr. Beáta Dupejová, neurologická ambulancia s.r.o.
  • Nová ulica 21, 974 04 Banská Bystrica
  • www.dupejova.sk
  • Beáta Dupejová, MD

Recruiting

Fakultná nemocnica s poliklinikou Žilina
  • Psychiatrické oddelenie
  • ul. Vojtecha Spanyola 43, 012 07 Žilina
  • www.fnspza.sk
  • Martina Hanzelová, MD

Recruiting

Neštátna psychiatrická ambulancia

Recruiting

Centrum zdravia R.B.K., s.r.o.
Univerzitná nemocnica Bratislava, Nemoc. Staré Mesto
  • I.Neurologická klinika LF UK a UNB
  • Mickiewiczova 13, 813 69 Bratislava
  • www.unb.sk
  • Peter Turčáni, Prof., MD, PhD.

Recruiting

2. LF Univerzity Karlovy a Fakultní nemocnice v Motole
  • Neurologická klinika
  • V Úvalu 84, 150 18 Praha 5 - Motol
  • www.fnmotol.cz
  • Jakub Hort, Prof., MD, PhD

Recruiting

Národní ústav duševního zdraví
  • Oddelení kognitivních poruch – AD centrum
  • Topolová 748, 250 67 Klecany
  • www.nudz.cz
  • Aleš Bartoš, Doc., MD, PhD

Recruiting

Fakultní nemocnice u sv. Anny v Brně
  • Centrum pro kognitivní poruchy, Neuro 2
  • Pekařská 53, 656 91 Brno
  • www.fnusa.cz
  • Kateřina Sheardová, MD

Recruiting

Fakultní nemocnice Hradec Králové
  • Neurologické oddelení
  • Sokolská 581, 500 05 Hradec Králové
  • www.fnhk.cz
  • Martin Vališ, Prof., MD, PhD
Medizinische Universität Graz
  • Universitatsklinik für Neurologie
  • Auenbruggerplatz 22, 8036 Graz
  • www.medunigraz.at
  • Reinhold Schmidt, Prof., Dr.

Recruiting

Universitätsklinikum Innsbruck
  • Department of Psychiatry
  • and Psychotherapy
  • Anichstrasse 35, 6020 Innsbruck
  • www.tirol-kliniken.at
  • Imrich Blasko, Ao.Univ.Prof., Dr., MSc.

Recruiting

Tiroler Landeskrankenanstalten GmbH
  • Department of Psychiatry
  • and Psychotherapy
  • Milser Strasse 10, 6060 Hall in Tirol
  • www.tirol-kliniken.at
  • Josef Marksteiner, Univ.Prof., Dr.

Recruiting

Karolinska Universitetssjukhuset Huddinge
  • Minnesmottagningen M51
  • SE-14186, SE-14186 Stockholm
  • www.karolinska.se
  • Niels Andreasen, MD, PhD

Recruiting

Sahlgrenska Universitetssjukhuset
Uppsala University Hospital
  • Department of Geriatrics
  • SE-75185, SE-75185 Uppsala
  • www.akademiska.se
  • Lena Kilander, MD, PhD

Recruiting

Skånes Universitetssjukvård Malmö
  • VE Minnessjukdomar
  • Simrisbanvägen 14, SE-20502 Malmö
  • www.skane.se
  • Henrik Östlund, MD

Recruiting

Cluj-Napoca Emergency Clinical County Hospital
  • 43 Victor Babes Street, 400012 Cluj-Napoca
  • www.scju-cluj.ro
  • Horia Coman, Prof., MD, PhD
Spitalul Clinic Judetean de Urgenta Sf. Apostol Andrei
Psihomedical Consult SRL
  • Austrului str, no 52 2nd district, 024074 Bucharest
  • www.psihomedical.ro
  • Catalina Tudose, Prof., MD, PhD

Recruiting

Dr. C. Davila Emergency University Central Military Hospital
  • 88 Mircea Vulcanescu Street, 10825 Bucharest
  • www.scumc.ro
  • Daniel Vasile, Assoc. Prof., MD, PhD
"Dr. Constantin Gorgos" Psychiatry Hospital Titan

Recruiting

Neuropsychiatry Clinical Hospital
  • 99 Calea Bucuresti Street, 200473 Craiova
  • www.scnpc.ro
  • George Mihai Badescu, MD, PhD

Patient’s Room

Patientenzimmer

Pre pacienta

Pro pacienta

Patient’s Room

Patientenzimmer

Pre pacienta

Pro pacienta

Language:Sprache:Jazyk:Jazyk:

Alzheimer’s disease (AD) is an age-related progressive neurodegenerative disorder with an enormous unmet medical need. While the number of people suffering from AD is rising quickly, no effective treatments are available for the disorder. Symptomatic therapy, the most common therapeutic approach, is not able to stop progression of the disease. Therefore much attention is now being directed at the development of novel disease modifying therapeutic approaches, aiming to stop the disease and repair the damaged brain.

Alzheimer’s disease is characterized by the presence of neurofibrillary tangles consisting of diseased forms of protein tau and senile plaques composed of amyloid beta protein. Several studies demonstrated that distribution of neurofibrillary tangles in Alzheimer’s disease correlates well with neuronal loss and also with severity of dementia. We have therefore suggested that a therapy targeting diseased forms of tau protein has the potential to protect neurons from neurofibrillary degeneration.

AXON Neuroscience developed active immunotherapy AADvac1 targeting diseased forms of tau protein. AADvac1 stimulates the patient’s immune system to generate specific antibodies against diseased forms of tau protein and thus protects the brain from neurodegeneration.

AXON Neuroscience has successfully started recruitment of patients in the phase II study of AADvac1, which will be conducted in several European contries. This study is designed to assess the safety and efficacy of AADvac1 in the treatment of Alzheimer's disease.

The study will be carried out in accordance with the ethical and scientific principles of Declaration of Helsinki, the ICH Guideline on Good Clinical Practice, the EU Clinical Trials Directive, as well as local regulations.

For more information visit AADvac1 AD Phase II study.

Die Alzheimer-Krankheit ist eine altersbedingte progressive neurodegenerative Störung mit erheblichem unerfülltem Behandlungsbedarf. Trotz eines schnell wachsenden Personenkreises, der an der Alzheimer-Krankheit leidet, existiert keine effektive Behandlungsmethode dieser Störung. Die meisten Therapiemethoden sind symptomatisch, sie können aber den Krankheitsfortschritt nicht stoppen. Deshalb ist heute große Aufmerksamkeit auf die Entwicklung neuer Therapiemethoden gerichtet, die den Verlauf der Krankheit mit dem Ziel beeinflussen können, den Krankheitsfortschritt zu stoppen und die Gehirnschädigung in Ordnung zu bringen.

Für die Alzheimer-Krankheit sind sogenannte Neurofibrillenbündel, die pathologische Form vom Tau-Protein und Eiweißablagerungen, sogenannte Plaques aus Beta-Amyloid-Protein charakteristisch. Einige Studien zeigen, dass die Verteilung der Neurofibrillenbündel bei Alzheimer-Kranken mit dem Verlust von Nervenzellen und mit der Schwere der Erkrankung stark zusammenhängen. Deshalb legen wir nahe, dass eine Therapie, die sich auf pathologische Formen von Tau-Protein konzentriert, das Potenzial hat, Nervenzellen vor neurofibrillärer Degeneration zu schützen.

AXON Neuroscience entwickelte die aktive Immuntherapie AADvac1, die sich auf pathologische Tau-Proteinformen konzentriert. Der Impfstoff AADvac1 stimuliert das Immunsystem von Patienten, um spezifische Antikörper gegen pathologische Tau-Proteinformen zu bilden und so das Gehirn vor Degeneration der Nervenzellen zu schützen.

AXON Neuroscience hat erfolgreich mit der Patientenrekruitierung für die Klinische Studie der Phase II mit AADvac1 begonnen, die in mehreren europäischen Ländern durchgeführt wird.

Diese Studie ist darauf ausgelegt, die Sicherheit und Wirksamkeit des Impfstoffes AADvac1 in der Behandlung von Alzheimer-Krankheit zu bewerten.

Diese klinische Studie wird im Einklang mit ethischen Prinzipien und wissenschaftlichen Grundsätzen der Deklaration von Helsinki, der Richtlinie der Internationalen Konferenz zur Harmonisierung zur Guten Klinischen Praxis, den EU Richtlinien zu klinischen Prüfungen sowie gemäß länderspezifischer Vorschriften realisiert.

Ausführliche Informationen finden Sie in der AADvac1 AD Phase II Studie.

Alzheimerova choroba je vekovo podmienená progresívna neurodegeneratívne ochorenie s enormne veľkými nenaplnenými liečebnými potrebami. Hoci sa rýchlo zvyšuje počet osôb, ktoré trpia Alzheimerovou chorobou, v súčasnosti neexistuje efektívna liečba tohto ochorenia. Najčastejším liečebným postupom je liečba zmierňujúca príznaky, ktorá však nedokáže zastaviť postup ochorenia. Preto sa v súčasnosti veľká pozornosť venuje vývoju úplne nových liečebných postupov, ktoré dokážu ovplyvniť priebeh choroby, s cieľom zastaviť postup ochorenia a opraviť poškodenia v mozgu.

Pre Alzheimerovu chorobu je typický výskyt tzv. neurofibriálnych klbiek ktoré obsahujú chorobnú formu proteínu tau a tzv. senilné plaky zložené z Beta-amyloidu. Niektoré štúdie preukázali, že výskyt neurofibriálnych klbiek u pacientov s Alzheimerovou chorobou má súvislosť so stratou nervových buniek a tiež so závažnosťou ochorenia. Preto sme navrhli liečbu zameranú na patologickú formu proteínu tau, ktorá má predpoklady ochrániť nervové bunky pred neurofibriálnou degeneráciou.

Spoločnosť AXON Neuroscience vyvinula aktívnu imunoterapiu AADvac1, ktorá je zameraná na chorobné formy proteínu tau. Vakcína AADvac1 stimuluje pacientov imunitný systém s cieľom vytvoriť špecifické protilátky proti tomuto proteínu tau a tým chrániť mozog pred degeneráciou nervových buniek.

Spoločnosť AXON Neuroscience úspešne začala nábor pacientov pre AADvac1 fázu II klinického skúšania, ktoré sa bude vykonávať v niekoľkých európskych krajinách. Účelom tohto skúšania je doplniť údaje o bezpečnosti a posúdiť účinnosť vakcíny AADvac1 pri liečbe Alzheimerovej choroby.

Toto skúšanie bude vykonané v súlade s etickými a vedeckými zásadami Helsinskej deklarácie, Smerníc Medzinárodnej konferencie pre harmonizáciu o správnej klinickej praxi, Smerníc EÚ o klinickom skúšaní, a s miestnymi predpismi.

Podrobnejšie informácie sa uvádzajú v štúdii AADvac1 AD Fáza II.

Alzheimerova nemoc je věkově podmíněná progresivní neurodegenerativní porucha s enormně velkými nenaplněnými léčebnými potřebami. Ačkoli se rychle roste počet osob, které trpí Alzheimerovou nemocí, neexistuje efektivní léčba této poruchy. Nejčastějším léčebným postupem je symptomatická terapie, která však nedokáže zastavit postup onemocnění. Proto se v současnosti věnuje velká pozornost vývoji zcela nových léčebných postupů, které dokážou ovlivnit průběh choroby, s cílem zastavit postup onemocnění a napravit poškození v mozku.

Pro Alzheimerovu nemoc je typický výskyt tzv. neurofibrilárních klubek, která pozůstávají z patologických forem proteinu tau a tzv. senilní plaky složené z proteinu beta-amyloidu. Některé studie prokázaly, že výskyt neurofibrilárních klubek u pacientů s Alzheimerovou nemocí souvisí se ztrátou nervových buněk a rovněž se závažností onemocnění. Proto jsme navrhli léčbu zaměřenou na patologickou formu proteinu tau, která má předpoklady ochránit nervové buňky před neurofibrilární degenerací.

Společnost AXON Neuroscience vyvinula aktivní imunoterapii AADvac1, která se zaměřuje na patologické formy proteinu tau. Vakcína AADvac1 stimuluje pacientův imunitní systém s cílem vytvořit specifické protilátky proti patologickým formám proteinu tau, a tím chránit mozek před degenerací nervových buněk.

Společnost AXON Neuroscience úspěšně zahájila nábor pacientů pro fázi II klinického zkoušení AADvac1, které se bude provádět v několika evropských zemích. Účelem tohoto zkoušení je posouzení bezpečnosti a účinnosti vakcíny AADvac1 při léčbě Alzheimerovy nemoci.

Toto zkoušení bude provedeno v souladu s etickými a vědeckými zásadami Helsinské deklarace, směrnic Mezinárodní konference pro harmonizaci o správné klinické praxi, směrnic EU o klinickém testování, a s místními předpisy.

Podrobnější informace jsou uvedeny ve studii AADvac1 AD Fáze II.

Press room

Events

  • Upcoming events
  • Past events
  • Alzheimer´s Association International Conference
  • DateJuly 24-28, 2016LocationToronto, CanadaLinkwww.alz.org/aaic
  • 10th International Conference on Frontotemporal Dementias
  • DateAugust 31-September 2, 2016LocationMunich, GermanyLinkwww.icftd2016.de
  • 14th International Athens/Springfield Symposium on Advances in Alzheimer Therapy
  • DateMarch 9-12, 2016LocationAthens, GreeceLinkwww.ad-springfield.com

The seventh conference on Clinical Trials on Alzheimer's Disease in Philadelphia last month covered everything from a sprinkling of new trial results to a new focus on tau PET imaging to a plea from former FDA honcho Rusty Katz that trialists stop obsessing over disease modification and aggressively pursue big therapeutic effects instead. Madolyn Rogers and Gabrielle Strobel close out their report on the meeting with a look at the role brain amyloid plays in AD, and a review of what new treatments may be in store for 2015.

  • Alzheimer´s Association International Conference
  • DateJuly 18-23, 2015LocationWashington D.C., USALinkwww.alz.org/aaic

Join international investigators, clinicians and care providers as they gather to share the latest study results, theories and discoveries that will help bring the world closer to breakthroughs in dementia science.

  • The 12th International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders
  • DateMarch 18-22, 2015LocationNice, FranceLinkwww.kenes.com/adpd

The 12th International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (AD/PDTM 2015) will build on the well-earned reputation of previous AD/PDTM meetings for unraveling the mechanisms and improving the treatment of Alzheimer's, Parkinson's and other related neurodegenerative diseases. Conference attendees will gain unique and powerful insights into the latest research, developments, and treatments.

  • 7th Clinical Conference on Alzheimer‘s Disease
  • DateNovember 20-22, 2014LocationPhiladelphia, USALinkwww.ctad.fr

Alzheimer’s disease is one of the most important health challenges facing aging populations worldwide. The development of the next generation of Alzheimer’s disease drugs is becoming essential to face up to this challenge. We learned in San Diego of new pathways identified with biomarkers, facilitating novel trial designs for studies of tau-based therapies and other disease-modifying drugs including immunotherapy.

  • Alzheimer's Association International Conference® 2014
  • DateJuly 12-17, 2014LocationCopenhagen, DenmarkLinkwww.alz.org/aaic

Join us from July 12-17 in Copenhagen for AAIC 2014®, where thousands of researchers from more than 60 countries will gather to reveal the latest study results, theories and discoveries bringing the world closer to breakthroughs in dementia science.

  • 13th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy 2014
  • DateMarch 26-29, 2014LocationGeneva, SwitzerlandLinkwww.siumed.edu/cme/alzheimer

Leading scientists will discuss new targets and drugs for the treatment of Alzheimer’s disease and novel approaches to current therapy. An oral communication session will be open to young scientists.We expect approximately 1500 participants, mostly neurologists, psychiatrists, geriatricians and pharmacologists.

The Alzheimer's Association International Conference (AAIC) is the world's premier forum for the reporting and discussion of groundbreaking research and information on the cause, diagnosis, treatment and prevention of Alzheimer's disease and related disorders. As a part of the Association's research program, AAIC serves as a catalyst for generating new knowledge about Alzheimer's and fostering a vital, collegial research community.

The 6th annual CtaD conference will relate experiences from international teams covering every stage of clinical trials in Alzheimer’s Disease. From animal models to human trials, CtaD 2013 provides an opportunity to learn about the latest results in drug trials as well as important topics such as internet screening of cognition to recruit for clinical trials, designing drug trials taking into account neuropsychiatric symptoms of AD, down syndrome as well as ethical issues and methodological considerations.

AD/PD™ 2013, the 11th International Conference on Alzheimer’s and Parkinson’s Disease, co-organized by Abraham Fisher, Israel Hanin, Roger Nitsch and Manfred Windisch, is a landmark event bringing together over 3,000, neuroscientists, pharmacologists and clinicians to study the hot topics, similarities and differences and scientific breakthroughs associated with Alzheimer’s Disease, Parkinson’s Disease and related neurological disorders, and to evaluate advances that might ameliorate many of these diseases.

  • 8th International Winter Conference on Alzheimer's Disease 2012
  • DateDecember 7-10, 2012LocationZuers, AustriaLinkwww.ad-zuers.com

In a snowy mountain town in Austria, 75 scientists met from 7-10 December 2012 for the 8th International Winter Conference on Alzheimer’s Disease. They traded data and discussion of treatment approaches in the kind of cooped-up, homey atmosphere that brings down barriers when a diverse group of scientists stay together from breakfast until dinner to present, question, and debate science.

Media kit

Media contact

Michael Matis

Career

Job Positions

Transgenic
technology expert
Head Veterinary
Doctor
Neuroproteomist
Contract Length

3 years

Institution

AXON Neuroscience SE, Bratislava

Department

Centre for Diagnostic and Validation Platforms

Job Description

A postdoctoral position is available for a period of 3 years at Slovak biotech company AXON Neuroscience SE. Centre for Diagnostic and Validation Platforms focuses on development of novel animal models for Alzheimer’s and Parkinson’s disease.

We are looking for highly motivated candidates with a strong background in neuroscience and excellent expertise in transgenic technologies (pronuclei microinjections), embryofreezing and embryotransfer and stereotaxic surgery.

Experience with laboratory animals, strong scientific aspirations and English are required.

Contact Information
Select files
Contract Length

3 years

Institution

AXON Neuroscience SE, Bratislava

Department

Centre for Diagnostic and Validation Platforms

Job Description

The position is available in the new animal facility at Slovak biotech company - AXON Neuroscience SE. Centre for Diagnostic and Validation Platforms focuses on development of novel animal models for Alzheimer’s and Parkinson’s disease.

The successful candidate will perform and oversee all veterinary activities in the rodent facility, oversee the breeding plan and its accurate fulfilment, coordinate the technical staff and assume responsibility for work safety and hazard protection.

Experience with laboratory animals and English language required.

Contact Information
Select files
Contract Length

3 years

Institution

AXON Neuroscience SE, Bratislava

Department

Neuroproteomics Laboratory

Job Description

The candidate should have PhD in the field biology/biochemistry and an excellent experience and track record in proteomics, including chromatography and mass spectrometry. He/she should have knowledge based methods competence in protein isolation, identifications of modifications and protein-protein interactions. Experience in structural analysis is advantageous (e.g. mass spectrometry identification of native crosslinks, hydrogen-deuterium exchange, surface mapping by protein modification, etc.).

The successful candidate should be highly motivated, actively seeking and implementing knowledge from broad spectrum of life sciences and able to fully manage own project(s).

In addition, he/she should have high command of written and oral English, computer literacy and ability to work in teams.

Contact Information
Select files

Overview

Recognises that creativity is at the heart of success

We recognize that creativity is at the heart of success

At AXON Neuroscience we work together every day to discover, develop, and deliver breakthrough therapies for patients suffering from Alzheimer’s disease.

We provide our employees with challenging workplace where each position offers an opportunity for professional development. Passion for innovation and novelty plays leading roles in our work.

Encourages to think outside the box

We encourage thinking outside the box

We offer exciting and challenging careers within a collaborative and knowledge-driven environment where ideas and skills are highly valued; and where individual contributions are recognised and rewarded.

Employees take advantage of opportunities to attend international conferences, participate in international professional associations, and publish their research in scientific journals.

Employees create a can-do atmosphere

Employees create a can-do atmosphere

We are always on the lookout for people who are extremely capable, talented, and enthusiastic, for strongly motivated people who are looking for an environment that values all of these qualities in its employees.

Join us and you will have an opportunity to grow and develop your career with the company. If you have an interest in becoming a member of our team, please submit your CV for a position.

Contact

Contact us

AXON Neuroscience SE

AXON Neuroscience CRM Services SE

AXON Neuroscience R&D Services SE

Google Map